– Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M
– Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025
– Entered strategic research collaboration with BioMarin valued at over $370M
NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights…
Global Times: Feng Jicai leads efforts to preserve China's cultural heritage through art, literature, and…
Hanover, MA , April 20, 2025 (GLOBE NEWSWIRE) -- Boston Hemp Inc., a leader in…
NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights…
NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor…
The latest data release from the Commodity Futures Trading Commission (CFTC) reveals a marginal improvement…
This website uses cookies.